Efficacy data from Cohort 1 demonstrate substantial evidence of benefit for adjuvant abemaciclib+endocrine therapy in patients with HR+, HER2− early BC at high risk of recurrence (ClinicalTrials.gov: NCT03155997 [monarchE]). This evidence concerns the gene HR and breast cancer.